Please assess the completion status of the following clinical trial:

Trial Title: Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed diagnosis of breast cancer with documented progressive disease~  * Metastatic disease~* Measurable disease as defined by RECIST criteria or evaluable disease~* Must have received at least one prior chemotherapy regimen for metastatic breast cancer~  * Patients refusing all other chemotherapy for breast cancer may enroll without prior treatment~* Patients with HER2-overexpression disease must have been previously treated with trastuzumab (Herceptin®)~* Patients with stable brain metastases are eligible~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Menopausal status not specified~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Life expectancy ≥ 12 weeks~* Absolute Neutrophil Count (ANC) ≥ 1,000/mm³~* Platelet count ≥ 100,000/mm³~* Creatinine ≤ 1.5 times upper limit of normal (ULN)~* aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)~* Total bilirubin ≤ 1.5 times ULN~* Able to take oral medications and maintain hydration~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for 6 months after treatment~* No severe concurrent illness including, but not limited to, any of the following:~  * Congestive heart failure~ * Significant cardiac disease~ * Uncontrolled hypertension~* Must be able to read and speak English~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* At least 2 weeks since prior treatment, including chemotherapy, hormonal therapy, trastuzumab (Herceptin®), or other targeted therapies~* Prior bevacizumab allowed if discontinued for any reason other than toxicity~* No potent inducers or inhibitors of CYP3A4 enzymes that effect the metabolism of sunitinib malate~* No prior sunitinib malate~* No other concurrent investigational therapy~* No concurrent radiotherapy~* Concurrent bisphosphonates allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Sunitinib, Cyclophosphamide, and Methotrexate (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).